Abbott Laboratories: Tailwind From Healthcare Spending And Emerging Markets

  I have been a shareholder in Abbott Laboratories (ABT) since the acquisition of St. Jude in 2016. I believe this is a very good stock to own for the long run, not because of the dividend, but because of the potential long-term returns. Furthermore, Abbott’s products are needed both in good and bad times….